AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05991414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual pharmacist care
Description: Participants will come into the pharmacist at baseline, 12- and 24-weeks to have their BP taken by the pharmacist. Pharmacist will provide education and counseling. Pharmacist will send BP readings to participants prescribing clinician with no recommendations for changes to antihypertensive therapy. After 6-months participants will be offered a home BP monitor and instructions on use.
Study NCT04435704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intravenous Oxytocin
Study NCT06306105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine Collagen Peptides
Description: consume 1 bottle per day
Study NCT06306105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo drink
Description: consume 1 bottle per day
Study NCT04474080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Peer Support Platform
Description: The intervention program will consist of 6 virtual 30-minute sessions delivered across three months. Sessions will follow a structured format including: check-in, issue identification \& context, facilitated discussion, environmental strategies, occupational strategies, experiential component, as well as summary and sign-out. Meetings will finish with a stress relieving activity, to be performed together on the web-based platform. The facilitated discussions will follow important themes including focus on self, patients, and external stressors.
Study NCT04474080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Period
Description: The control period will be the time prior to randomization and commencement of the intervention, whereby residents will continue with their regular academic day activities during the allotted intervention time
Study NCT05596058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task protocol: active exercises with concomitant cognitive training in executive functions
Description: The active exercise tasks will be associated with concomitant cognitive tasks specifically relying on executive function.~The goal is to engage the three core executive functions: inhibition (the ability to inhibit automated responses), working memory (the ability to hold, process, and manipulate information in mind) and shifting (the ability to change stimulus-response associations for performing an ongoing task).~Patients will be exposed to different cognitive tasks during physical activity such as walking or running on the treadmill, indoor cycling and balance exercises.
Study NCT05596058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active exercise
Description: Physical activity and motor task only
Study NCT05596058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive task only
Description: cognitive exercise in executive functions
Study NCT04869228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT0918 tablets or placebo
Description: GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals
Study NCT04869228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GT0918 tablets or placebo
Description: GT0918 tablets or placebo: oral, 1 time / day, 2 tablets / time, after meals
Study NCT05077644 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stella (TM) Mobile Application
Description: Treatment of mild-to-moderate postpartum depression (PPD) using Cognitive Behavioral Therapy techniques.
Study NCT05342506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab + ScTIL
Description: Toripalimab (80 mg iv) 24 hours before or concomitantly with ScTIL 3-5x10\^9 intravenous reinfusion.
Study NCT06123325 — intervention group
Intervention type: PROCEDURE
Intervention: Clipping
Description: Microsurgical clipping of intracranial aneurysms involves craniotomy to access the brain, locating the aneurysm, and placing a small metal clip across its neck, thereby isolating it from normal blood circulation to prevent rupture.
Study NCT06123325 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular embolization
Description: Any endovascular embolization of intracranial aneurysms that involves navigating microcatheters through the vascular system to the site of the aneurysm and deploying materials like coils, flow-diverting stents, or endosaccular flow disruptors to occlude the aneurysm and reduce the risk of rupture.
Study NCT06123325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Surveillance imaging
Description: Surveillance imaging for brain aneurysms is a diagnostic approach that uses imaging techniques such as MRI, MRA, CTA, or DSA to regularly monitor the status of detected brain aneurysms. The goal is to track changes in the aneurysm's size, shape, or structure over time, which may indicate an increased risk of rupture. This ongoing assessment helps healthcare providers decide whether to continue monitoring or to consider treatment options, such as surgical clipping or endovascular coiling, based on the aneurysm's characteristics and the patient's risk factors.
Study NCT05794620 — intervention group
Intervention type: OTHER
Intervention: Stool sample
Description: Stool sample
Study NCT04251715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given intraarterially via HAI pump
Study NCT04251715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Given intraarterially via HAI pump
Study NCT04251715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy
Study NCT04251715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT04251715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT04251715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT05037877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HUM supplement
Description: HUM supplement - 1 capsule per day
Study NCT05037877 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement - 1 capsule per day
Study NCT04251715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05234229 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Collection of immunization status by questionnaire
Study NCT06054282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ready for Tonsillectomy educational mobile application
Description: The Ready for Tonsillectomy mobile application provides child-focused, procedure-specific education developed with feedback from patients, caregivers, and pediatric otolaryngologists. The application guides patients and their families through each aspect of the surgical experience, including reasons for tonsillectomy, how to prepare for surgery, anesthesia, and postoperative recovery. Diverse characters focus on the child's perspective in the treatment process, showing what happens at each step. Written at an early elementary reading level (available in English or Spanish), the text is integrated with graphics and animations. The application aims to promote active learning and equip patients with positive expectations and coping strategies as they approach surgery. It also prepares caregivers to navigate their child's surgery and optimize recovery. Notifications provide key information and reminders for caregivers to promote adherence and address common questions.
Study NCT06087926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transcranial magnetic stimulation (or TMS) is a non-invasive form of brain stimulation in which a magnetic pulse is applied directly to the scalp. TMS is FDA approved for the treatment of depression and other neuropsychiatric disorders and is regularly used in neurologic and psychiatric research.~ITBS is a particular TMS protocol which delivers the magnetic field in triplet bursts (three stimulations very close together at a frequency of 50 Hz). The triplet bursts are repeated at a rate of 5 Hz for 2 seconds (30 pulses), followed by 8 seconds rest, repeated 20 times for a total of 600 pulses. Each treatment lasts approximately 3 minutes.
Study NCT04728412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Oxygen Therapy (HFOT)
Description: HFOT administration in patients undergoing bronchoscopy under moderate sedation, affected by or at risk of hypoxemic and/or hypercapnic respiratory failure.
Study NCT05443646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W
Study NCT05443646 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: 45Gy/3Gy/3week
Study NCT05443646 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: 25Gy/2.5Gy/2week
Study NCT05222724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tachifene
Description: paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
Study NCT05222724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brufen
Description: ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).
Study NCT06435663 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Different methods of efficacy evaluation
Description: When the treatment method remains unchanged, compare the accuracy data of the effectiveness evaluation between the two groups, and verify that the ultra-fine blood flow imaging technology (SMI) is superior to the organ contrast-enhanced ultrasound evaluation method in the efficacy evaluation after HIFUA treatment.
Study NCT06435663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Different methods of efficacy evaluation
Description: When the treatment method remains unchanged, compare the accuracy data of the effectiveness evaluation between the two groups, and verify that the ultra-fine blood flow imaging technology (SMI) is superior to the organ contrast-enhanced ultrasound evaluation method in the efficacy evaluation after HIFUA treatment.
Study NCT06139276 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small Needle-Knife
Description: The small needle-knife therapy originated from the ancient Chinese acupuncture instrument known as the Pi needle from the Nine Needles, which resembled a sword, had two sharp edges, and was originally used for abscess drainage. It is currently widely applied in treating conditions such as myofascial adhesions, chronic pain, or nerve compression.~The small needle-knife features a flat and rounded tip design, with its handle made of solid steel. This construction provides excellent toughness and flexibility, minimizing tissue damage, and facilitating microadhesiolysis, an intervention aimed at releasing adhesions.
Study NCT06139276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment
Study NCT05842616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial doppler pulsatility index guided protocol
Description: Norepinephrine titration that will be guided by Transcranial doppler pulsatility index.
Study NCT05842616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mean arterial blood pressure guided protocol
Description: Norepinephrine titration that will be guided by Mean arterial blood pressure (MAP).
Study NCT06009939 — intervention group
Intervention type: OTHER
Intervention: Occlusion of the circulation in the arm and foot
Description: A blood pressure cuff occludes the circulation in the upper arm as well as around the ankle.
Study NCT06092723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects take two packs once a day, and make a 250 ml water solution for drinking.
Study NCT06092723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 1,Lactococcus lactis subsp. lactis, LY-66
Description: Subjects take two packs once a day, and make a 250 ml water solution for drinking.
Study NCT06092723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 2,Lactobacillus plantarum, PL-02
Description: Subjects take two packs once a day, and make a 250 ml water solution for drinking.
Study NCT06092723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 3,Lactococcus lactis subsp. lactis, LY-66+Lactobacillus plantarum, PL-02
Description: Subjects take two packs once a day, and make a 250 ml water solution for drinking.
Study NCT05303220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days
Study NCT05303220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified Dose on specified days
Study NCT04716491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention to decrease disruptive sleep in patients undergoing percutaneous intervention to treat cardiac disorders admitted to the ICU: ear protector and eye mask.
Description: When they meet the inclusion criteria and accept to participate in the study, the interventionist nurse will explain to the patient the objectives and protocol of the study, apply the consent form and the instruments for assessing sleep (pittsburgh), trait and state anxiety (STAI). Then the software will be randomized and after defining the group, the nurse will guide the patient on the use of the devices from 9:00 am until the final awakening in the morning. Control group participants will only complete the assessment instruments. Noise and brightness will be measured at randomization of participants. The following morning, the visual sleep scale and the sleepiness scale will be applied for both groups, in addition to filling in information regarding the length of time the devices stay with patients at night and the clinical data that will be collected until discharge from the hospital. ICU, when independent of the group, the state anxiety instrument will be applied.
Study NCT05324397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROMARK System
Description: The NEUROMARK™ System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
Study NCT03629327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA 81mg
Description: Participants will be randomized to take 81mg orally on a daily basis for a duration of 6 months
Study NCT03629327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants will be randomized to take nothing on a daily basis for a duration of 6 months
Study NCT03629327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA 325mg
Description: Participants will be randomized to take 325mg orally on a daily basis for a duration of 6 months
Study NCT05163080 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SurVaxM
Description: Consists of a synthetic peptide conjugate that stimulates immune responses capable of killing cancer cells that express the survivin molecule. Multiple copies of the multiplied peptide (SVN53-67/M57) are conjugated to Keyhole Limpet Hemocyanin (KLH) yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the wild-type survivin molecule expressed by tumor cells. The survivin peptide in SurVaxM is a defined antigenic peptide comprised of 15 amino acids that encompass multiple epitopes capable of binding human MHC Class I and murine H2-Kb molecules. SurVaxM also contains a core antigenic epitope that has been modified by substitution of methionine for cysteine at amino acid position 57 (i.e., M57).
Study NCT05163080 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SurVaxM
Description: Consists of a synthetic peptide conjugate that stimulates immune responses capable of killing cancer cells that express the survivin molecule. Multiple copies of the multiplied peptide (SVN53-67/M57) are conjugated to Keyhole Limpet Hemocyanin (KLH) yielding a molecule designated as SVN53-67/M57-KLH. The SVN53-67/M57-KLH conjugate (SurVaxM)produces immune responses in mice and humans that are cross-reactive to the wild-type survivin molecule expressed by tumor cells. The survivin peptide in SurVaxM is a defined antigenic peptide comprised of 15 amino acids that encompass multiple epitopes capable of binding human MHC Class I and murine H2-Kb molecules. SurVaxM also contains a core antigenic epitope that has been modified by substitution of methionine for cysteine at amino acid position 57 (i.e., M57).
Study NCT05134584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: 290μg once daily, 4 weeks
Study NCT05134584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: 20mL once daily, 4 weeks
Study NCT05134584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazol
Description: 20mg twice daily for the first 10 days
Study NCT05134584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazol
Description: 20mg twice daily for the first 10 days
Study NCT05134584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itopride
Description: 50mg three times daily for the first 10 days
Study NCT05134584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itopride
Description: 50mg three times daily for the first 10 days
Study NCT04957485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tecovirimat
Description: oral antiviral
Study NCT04957485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smallpox and Mpox Vaccine
Description: vaccine
Study NCT04957485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smallpox and Mpox Vaccine
Description: vaccine
Study NCT04957485 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TPOXX Placebo
Study NCT05335330 — intervention group
Intervention type: OTHER
Intervention: Evaluation of biomechanics and viscoelastic properties of Thoracolumbar fascia
Description: The biomechanical and viscoelastic properties of the Thoracolumbar fascia will be measured in the side line position. Measurements will be taken from three different points; L1, L3-4 and L5 level.
Study NCT04771156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 0.5mg/kg will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of Ketorolac
Study NCT04771156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline will be administered intra-operatively at the conclusion of the case and 3 more doses scheduled every 8 hours in the first 24 hours post-operatively for a total of 4 doses of normal saline.
Study NCT06478420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron BA.5 SARS-CoV-2 challenge virus
Description: The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.
Study NCT04865276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
Description: Integrated tobacco cessation intervention delivered by Community Health Workers with the support of an App (mHealth) + Tobacco cessation program at the public health system
Study NCT05627830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: Prolotherapy is an injection treatment used to relieve pain. And for Cellular Regeneration
Study NCT05627830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Prolotherapy is an injection treatment used to relieve pain. And for Cellular Regeneration
Study NCT06077968 — intervention group
Intervention type: BIOLOGICAL
Intervention: Prior standard of care receipt of Pfizer's ABRYSVO vaccine
Description: Participants will receive Pfizer's ABRYSVO vaccine as part of standard of care. Vaccine is not administered in this study.
Study NCT04166643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHHIP PLUS
Description: Worksite health promotion and occupational health and safety (total worker health)
Study NCT04166643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education only control
Description: Education at the start of the project
Study NCT06318741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise on the treadmill+For both groups, patients will be recommended joint range of motion (ROM), stretching, strengthening, posture and balance and flexibility exercises for all joints.
Description: aerobic exercise on the treadmill
Study NCT06318741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Walking at an intensity of 12-13 RPE+For both groups, patients will be recommended ROM, stretching, strengthening, posture and balance and flexibility exercises for all joints.
Description: Walking at an intensity of 12-13 RPE